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ABSTRACT. Inadequate drug plasma levels have been asso-
ciated with the administration of phenytoin with enteral feed-
ings through nasogastric (NG) tubes. It is demonstrated in this
study that loss of phenytoin to tubing is a function of pH.
Nonionized phenytoin is irreversibly bound to NG tubing from
solution at the pH of enteral nutrient solutions while this is
not the case for anionic phenytoin in unbuffered water or saline.
In experiments pulsing phenytoin through glass us NG tubing
perfused with buffer at varying pH, reversible loss to tubing
was observed at high pH while irreversible loss was observed
at low pH. In addition, the irreversible loss of phenytoin was
greater in NG tubing than glass particularly at low pH. It is
suggested that in those cases where tubing is placed into the
duodenum, inadequate gastrointestinal residence time for dis-
solution of phenytoin solid and suspension dosage forms cou-
pled with irreversible drug loss from solution to NG tubing will
result in decreased phenytoin absorption and subsequently
lower drug plasma levels. (Journal of Parenteral and Enteral
Nutrition 14:513-516, 1990)
Numerous reports describing an interaction with na-
sogastric (NG) enteral feedings and the antiepileptic
phenytoin (PHT) have appeared in the literature since
1982. These reports include medical case studies as well
as in vivo and in vitro investigations designed to elucidate
the mechanism of this interaction. The case studies
reported clinical effects as a result of decreased PHT
plamsa levels in the presence of enteral NG feedings 1,2
and increased levels when feedings were discontinued.3~4
Because of the narrow therapeutic index of PHT, under
or overdosage results in more serious (and thus reporta-
ble) clinical events than are observed for other drugs.’
Recommendations for PHT administration with respect
to dosage and timing during enteral NG feeding sched-
ules remain unsettled. 1-4
In vitro studies have focused on PHT loss to NG
tubing3.6 and loss to enteral feeding components.7.8 In
this regard, binding to caseinate salt components of both
enteral feedings’ and dairy products’ has been implicated
while PHT loss to NG tubing from drug in suspension is
only significant when tubing irrigation is not performed
after PHT administration.~ 6 Interestingly, this latter
study suggested that greater loss to tubing occurred from
diluted as opposed to undiluted PHT suspensions.~ 6
In vivo studies in patients and normal subjects have
focused on the influence of oral (without NG tubing)
administration of enteral feedings on PHT bioavailabil-
ity from Dilantin suspensions&dquo; and capsules.ll Dilantin
(Parke Davis/Warner Lambert brand of PHT) suspen-
sion contains PHT free acid while the capsules contain
the sodium salt of PHT. Both studies failed to show
significant effects of these feedings on PHT bioavail-
ability as compared to controls over 80 hr1° and 48 hr.ll
However, it is our observation that the data in both
studies show higher PHT plasma levels up to 10 hr in
the presence of enteral feedings vs controls.
The results of this report were obtained following
studies in which nutrient effects on gastrointestinal (GI)
transit time in vivo12 and on PHT intestinal membrane
permeability in situ13 were observed. Delay of stomach
emptying in the fed-state, as monitored by radioteleme-
try, correlated with higher PHT plasma levels from orally
administered PHT capsules and suspensions in beagle
dogs.12 These results are consistent with the early time
data in human studies reported previously 10,11 and sug-
gest that if the dosage form is retained in the stomach,
greater GI residence time is available for dissolution of
PHT free acid.
In situ rat intestinal perfusions are performed in our
laboratories using glass or Teflon tubing as inlet and
outlet conduits. To measure intestinal drug uptake from
perfusion solution, drug loss to tubing under the perfu-
sion conditions is routinely evaluated in a control exper-
iment. In the case of PHT, minimal drug loss to glass
and Teflon tubing is observed in jejunal perfusions car-
ried out at pH 6.5 in which the flow rate is 0.5 ml/min
over 50-100 cm inlet tubing lengths.’’3 The observation
that greater PHT loss to NG tubing occurs from diluted
Dilantin suspensions’ prompted experimental measure-
ment of PHT loss to NG tubing as a function of drug
input and perfusion pH.
MATERIALS AND METHODS
Solutions of PHT free acid 80 uM (intrinsic aqueous
solubility 83 uM as determined in phosphate buffer at
pH 5 and pH 3) were prepared and traced with fiJ,5-
diphenyl-[ 4-14C]hydantoin (Amersham International, 58
mCi/nmol) at 5.93 x ~0’~ dpm/ml. Phosphate buffer at
65 mM was made up at pH 3, 7. and 12 and perfused
through 40 cm of both glass and NG tubing (Entriflex
distributed by Biosearch Medical Products) at 0.5 ml!
min. Entrifle·~ tubing is made of polwurethane and is
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lubricated on the interior and exterior surfaces with
Hydromer [polyviny lpyrrolidone (PVP), Hydromer Inc]
for insertion and removal of a flow-through stylet acti-
vated by injecting water to ease the passage of the tubing.
During the phosphate buffer perfusions, PHT solutions
were pulsed over a 30-sec time interval (tp, Table I) and
the time course of [14C]phenytoin output levels were
monitored by liquid scintillation counting. An additional
experiment was carried out in which perfusion of the
enteral nutrient solution, Osmolite HN (Ross Labora-
tories, pH 6.4), replaced the phosphate buffer and PHT
solution was pulsed as before.
RESULTS
Plots comparing PHT output from glass tubing us NG
tubing over 10-20 min are shown in Figure 1 for the
various perfusion solutions. In all cases, greater loss of
PHT to NG tubing was observed as compared with drug
loss to glass tubing (Table I, Fig. 1). Standard errors of
the mean are not given in the data presentation. How- 1
ever, duplicate experiments were performed which I
yielded equivalent results. The form of the data in these 1
plots can be compared with an ideal solute residence time i
distribution consistent with laminar flow of solvent fluid i
through the cylindrical tubing.&dquo; Deviations from the i
ideal flow pattern are suggestive of either solvent flow i
perturbations or solute interaction with the wall of the ,
tubing. The positioning of the tubing as well as its length
and flow rate used in these studies represent experimen-
tal conditions which minimize deviations from an ideal
laminar flow pattern. As a result, deviations from the
ideal solute residence time pattern (as generated by
laminar flow) are indicative of the type of interaction
occurring between the drug and the tubing wall, whether
reversible or irreversible.
PHT is a weak acid (pKa = 8.1) and the data in Figure
1 suggest that PHT anion binds reversibly to the NG
tubing while the uncharged free acid is removed in an
irreversible fashion. In particular, at pH 12 a greater
degree of tailing in the data is indicative of initial binding
of anion (the drug is totally ionized at this pH) while
little PHT mass is lost to the tubing (Table I) over the
total time course of the experiment. This suggests that
the binding of the anion is reversible because the drug
eventually exits the tubing as perfusion continues. The
data at pH 3 (in which the drug is totally nonionized)
does not show the tailing characteristic of reversible
binding (Fig. 1A) and in addition shows substantial loss
of PHT mass to NG tubing (Table I). This latter result
is suggestive of irreversible loss of nonionized PHT to
the NG tubing.
Although administration of PHT at pH 3 and 12 does
TABLE I
Total recovered mass (%) over 20 min in phosphate buffer (l4C traced
80 pM PHT; tp = 30 sec)
* pH 7 experiment was only carried out for 12 min with a to = 20
sec.
not reflect realistic clinical situations, it does represent
the extremes at which this drug would be presented to
the tubing in totally nonionized or ionized form, respec-
tively. The goal of this project was to separate PHT loss
from solution from events associated with dissolution of
solid PHT in capsule and suspension dosage forms. It
would be expected, for example, that if Dilantin Inject-
able (pH = 12) were administered through NG tubing in
Osmolite (pH = 6.4) feedings, that precipitation of the
free acid 15 would remove significantly more drug from
availability for absorption than removal by the NG tub-
ing. In this study, however, PHT was pulsed below its
intrinsic aqueous solubility (all the drug is in solution)
and loss of PHT in Osmolite to tubing (Fig. 1D) follows
a pattern similar to that seen in phosphate buffer at pH
7 (Fig. 1C).
DISCUSSION
Case studies in which PHT is administered by NG
tubing through which enteral feedings are given have
frequently resulted in depressed PHT plasma levels such
that the clinical consequences of effective underdosage
are observed.1-4 In vitro studies have demonstrated sig-
nificant loss of PHT when mixed with enteral nutrient
solutions,7,8 yet when PHT is administered orally with
enteral nutrient solutions without NG tubing, PHT bio-
availability is not compromised.1o,1l
In a study performed in beagle dogs,12 PHT capsules
were administered orally and stomach emptying was
monitored by radiotelemetry (Heidelberg capsule, Elec-
tro-Medical Devices).16 The study demonstrated that fed-
state delay of stomach emptying resulted in a longer GI
residence time over which PHT dissolution could occur.
[The fasted state stomach emptying pattern is dictated
by the cyclic nature of the migrating motor complex
(MMC)]. PHT plasma levels were seen to correlate with
the length of time between oral dosage and stomach
emptying. In one of the dogs, stomach emptying occurred
shortly after the PHT capsule was administered. Al-
though equal fluid volumes (150 ml water) were given
with the PHT capsule orally, drug plasma levels over 8
hr were 3-5 times lower in this dog. It is conjectured that
much of the undissolved, hydrophobic PHT does not
empty continuously from the stomach with the fluid
because it tends to aggregate as large particles&dquo; which
empty undissolved with the MMC.
In comatose patients, stomach emptying is compro-
mised and NG feeding tubes are frequently positioned to
empty into the duodenum.18 It is hypothesized that this
bypassing of the stomach followed by continuous enteral
feeding dictates inadequate time for PHT dissolution in
the GI tract and may contribute to the low PHT levels
observed in the case studies. 1-4
Furthermore, the in vitro studies reported here show
that a substantial amount of dissolved PHT is removed
by NG tubing. The Hydromer coating used to lubricate
the tubing interior and exterior surfaces is PVP. PHT-
PVP coprecipitates have been reported to markedly en-
hance PHT aqueous dissolution rates and subsequent GI
absorption. Supersaturation 2-3 times the aqueous PHT
solubility were maintained for 2 hr.19 Structural similar-
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FIG. 1. Recovery from pulsed [&dquo;C]PHT in phosphate buffer at pH = 3 (A), 12 (B), and 7 (C) and in Osmolite HN at pH = 6.4 (D) through
glass and NG tubing.
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ities between PVP and PHT suggest that the Hydromer
coating may be responsible for extracting nonionized
PHT from solution.
When a PHT suspension is administered by NG tub-
ing, short-term PHT blood levels may be decreased by
loss of dissolved PHT to the tubing and binding of PHT
to caseinate salt components of enteral feeding solu-
tions.’ Long-term PHT availability for absorption may
be reduced in those cases where undissolved PHT is not
held up in the stomach. When the tubing empties directly
into the small intestine and PHT is followed by contin-
uous feedings, GI residence time may not be adequate
for total PHT dissolution and overall PHT bioavailabil-
ity will be correspondingly compromised.
Previous in vitro studies have demonstrated negligible
loss of PHT to NG tubing.3°6 These studies were per-
formed with suspensions and not solutions. As a result
the drug lost to tubing from solution is negligible when
compared with the total drug potentially available from
undissolved drug in the suspension. This study demon-
strates that drug irreversibly lost from solution to NG
tubing is substantial if the pH is low enough for the
nonionized form to dominate. Furthermore, if the stom-
ach empties immediately or tubing is positioned to empty
into the duodenum, solid PHT will not be provided with
adequate GI residence time for complete dissolution.
Lastly, the in vitro data presented here are consistent
with the unusual finding of a previous study’ showing
greater loss of PHT to NG tubing from diluted Dilantin
suspensions than from undiluted suspensions.
If it is necessary to administer PHT by NG tube, it is
recommended that Dilantin capsules be given and that
the tubing be flushed with unbuffered solution (because
unbuffered sodium PHT dissolution results in high so-
lution pH, reducing irreversible drug loss to the tubing).
If the tubing empties into the duodenum, GI residence
time is compromised, providing less time for PHT dis-
solution. Variable absorption, in this latter situation, will
certainly be a function of both PHT dosage form and
choice of enteral nutrition.&dquo; PHT plasma levels should
be monitored in either situation because decreased ab-
sorption may couple with other contributions to drug
plasma level variability. Monitoring of plasma levels is
particularly important in the face of this variability
because of PHT’s narrow therapeutic index.
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